Protein Sequences: Not So Predictable After All
Scientists have believed for decades that the sequencing of the human genome would automatically yield the sequences of proteins, the functional products of genes, and thus lead to the unraveling of the mechanisms behind human cell biology and disease. However, a paper published in Science today by the Ludwig Institute for Cancer Research (LICR) describes a novel cellular process that casts some doubt on the accepted paradigm of deducing a protein’s sequence from the DNA sequence of its gene.
When a protein is called upon to act in a cellular process, segments (exons) of the gene’s DNA are transcribed into RNA fragments, which are then spliced (joined) together according to directions encoded by the DNA. The RNA transcript is then translated into amino acids which form a protein. When the protein is no longer required by the cell, it is degraded by a specialized complex called the ‘proteasome’. Although functionally different proteins can be produced from one gene sequence - by modification through the addition of small molecules to the amino acids, by truncation of the sequence, or by the translation of RNA transcripts that omit some exons - they are variations on a theme determined essentially by the gene’s DNA sequence. However scientists at the LICR Branch in Brussels, Belgium, have now shown that the sequence of a human protein can actually be altered by the proteasome in ways that are completely unpredicted by the gene sequence. The discovery is both a new process for protein processing and a novel, hitherto unsuspected role for the proteasome.
‘Post-translational splicing’ was discovered when the LICR team analyzed small protein sequences that activate the immune system in response to the presence of cancer cells. These ‘peptide antigens’ are created when the proteasome fragments a cancer-specific protein into peptides, which are then transported to the cell surface to mark the cell for immunological destruction. The team found that one peptide antigen, which stimulated the immune system to recognize and destroy melanoma cells, had a sequence quite unlike that predicted by its gene sequence. Upon investigating further, the researchers found that the proteasome had cut a peptide in three and had then rejoined the pieces so that the peptide antigen now recognized by the immune system was missing part of its original sequence.
“Post-translational splicing is a fascinating process in its own right,’ says Dr. Benoît Van den Eynde, the senior author of the study, “but it also has important implications for the design of cancer or HIV vaccines based on peptide antigens. Synthetic peptides being investigated in early-phase clinical trials of vaccines are usually designed based on the gene sequence of cancer-specific proteins. However post-translational splicing may be modifying the peptide antigens in ways that we haven’t even suspected before now.”
The issue of predicted versus post-translationally spliced, novel peptide antigens is a particularly important consideration when monitoring immunological responses to cancer vaccines in patients. The existing methodologies typically quantify the presence of T cells specific for the predicted peptide antigen, and would not detect T cells specific for the novel peptide antigen. Additional studies are required to determine if proteome-mediated post-translational splicing occurs in relation to cancer and/or virally-infected cells, and if so, the frequency of occurrence of such novel peptide antigens in these diseases.
The discovery of post-translational splicing has immunologists intrigued by the additional complications in antigen identification, and cell biologists excited by a new insight into the proteasome’s bag of tricks. However for geneticists and biochemists, the discovery of post-translational splicing may have produced a slight sense of unease. Until we know exactly when, why, and how often post-translational splicing occurs, we can no longer automatically assume that the human genome holds all the answers for predicting protein sequences.
Sarah White | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.
For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...
What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.
To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...
A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes
The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....
Larsen C Ice Shelf rift finally breaks through
A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...
Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision
Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...